B

뉴로핏

380550KOSDAQ소프트웨어 개발 및 공급업

56.4 / 100

Reference Date: 2026-04-13

Financial Score19.0 / 40
News Sentiment16.4 / 25
Momentum9.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 18.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Neurophet is a company specializing in medical imaging solutions for neurodegenerative diseases, particularly Alzheimer's, offering products like Neurophet AQUA AD, which assesses Amyloid-Related Imaging Abnormalities (ARIA) severity. The company holds international certifications such as CE, FDA 510K, and GMP, and provides Clinical Research Organization (CRO) services to support medical device development.

Number of Employees

139people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 14.434.0Point
PBR
12.46Industry Average 1.280.0Point

9.7x industry avg (risky)

ROE
Industry Average 1.363.5Point
Debt Ratio
2.55Industry Average 7.936.5Point

Half of industry avg (excellent)

Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
2.0 / 4

Detailed News Sentiment

9 totalPositive 3Neutral 1Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position3.0Point

52w lower range (36%)

Current 20,050Won52-week high 36,70052-week low 10,300
1-month return0.0Point

1m -18.83% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

7 totalPositive 1Neutral 6Negative 0
  • Positive주요사항보고서(유상증자결정)2026-04-10
  • Neutral주요사항보고서(전환사채권발행결정)2026-04-10
  • Neutral정기주주총회결과2026-03-30
  • Neutral감사보고서제출2026-03-20
  • Neutral사업보고서 (2025.12)2026-03-20